List of Suppliers' Thickeners And Stabilizers Excipients Application used in Glecaprevir on PharmaCompass.com

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 2 KDMF, 3 Listed Suppliers, $ API Reference Price

3 API Suppliers
2 KDMF
3 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

19 Intermediates Suppliers

19 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 2 FDA Orange Book, 1 Europe, 2 Canada

5 FDF Dossiers
2 FDA Orange Book
1 Europe
2 Canada

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 SPI Pharma, 1 Seqens, 3 DKSH, 2 Jai Radhe Sales, 1 PMC Isochem, 2 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 2 Alcedo Pharmachem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 BASF, 1 Bioplus Life Sciences, 3 DFE Pharma, 2 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 1 Ingredion Pharma Solutions, 14 Kerry, 3 Microlex e.U, 1 NEWEDGE Overseas, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 Sigachi Industries, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders, 15 Direct Compression, 12 Disintegrants & Superdisintegrants, 9 Lubricants & Glidants, 8 Film Formers & Plasticizers, 8 Granulation, 7 Coating Systems & Additives, 5 Co-Processed Excipients, 4 Emulsifying Agents, 3 Solubilizers, 3 Thickeners and Stabilizers, 2 Taste Masking, 2 Coloring Agents, 2 Topical, 2 Controlled & Modified Release, 2 Chewable & Orodispersible Aids, 2 Parenteral, 1 API Stability Enhancers, 1 Surfactant & Foaming Agents, 1 Rheology Modifiers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 34 NEWS #PharmaBuzz

media
3 DATA COMPILATION #PharmaFlow
34 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 Finished Drug Prices, 6 Annual Reports

globalSalesInformation
1 Finished Drug Prices
6 Annual Reports

MARKET PLACE

3 APIs, 1 FDF Dossiers

marketPlace
3 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

40 US Patents, 8 US Exclusivities

patents
40 US Patents
8 US Exclusivities

Glecaprevir PMC Isochem

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 42,183

MARKET PLACE

API

FDF

19INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

12,842

Finished Drug Prices

69 RELATED EXCIPIENT COMPANIES

120EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Abt-493, Glecaprevir [usan], 1365970-03-1, A-1282576.0, K6buu8j72p, A-1282576

Molecular Formula

C₃₈H₄₆F₄N₆O₉S

Molecular Weight

838.9 g/mol

InChI Key

MLSQGNCUYAMAHD-ITNVBOSISA-N

FDA UNII

K6BUU8J72P

Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance mutations of the virus. In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir. The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir resistance. Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both. Hepatitis C viral infection often leads to decreased liver function and subsequent liver failure, causing a significantly negative impact on the patients' quality of life. The ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection. In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of 93% across genotypes 1a, 2a, 3a, 4, 5 and 6.

Glecaprevir is a Hepatitis C Virus NS3/4A Protease Inhibitor. The mechanism of action of glecaprevir is as a HCV NS3/4A Protease Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 1A2 Inhibitor, and UGT1A1 Inhibitor.

1 2D Structure

Glecaprevir

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide

2.1.2 InChI

InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1

2.1.3 InChI Key

MLSQGNCUYAMAHD-ITNVBOSISA-N

2.1.4 Canonical SMILES

CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C

2.1.5 Isomeric SMILES

CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C

2.2 Other Identifiers

2.2.1 UNII

K6BUU8J72P

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Abt-493

2.3.2 Depositor-Supplied Synonyms

1. Abt-493

2. Glecaprevir [usan]

3. 1365970-03-1

4. A-1282576.0

5. K6buu8j72p

6. A-1282576

7. A-12825760

8. 1365970-03-1 (free)

9. Abt 493

10. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-[(1r,2r)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide

11. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-{(1r,2r)-2(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10carboxamide

12. Unii-k6buu8j72p

13. Maviret

14. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-[(1r,2r)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop Ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide

15. O31

16. Glecaprevir [mi]

17. Abt-493(glecaprevir)

18. Glecaprevir [inn]

19. Glecaprevir (usan/inn)

20. Glecaprevir [who-dd]

21. Schembl883097

22. Abt493

23. Chembl3545363

24. Gtpl11267

25. Glecaprevir [orange Book]

26. Dtxsid901027945

27. (1r,14e,18r,22r,26s,29s)-26-tert-butyl-n-[(1r,2r)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide

28. Amy38157

29. Ex-a1940

30. Mavyret Component Glecaprevir

31. Bdbm50573891

32. S5720

33. Cs-8098

34. Db13879

35. Ac-33419

36. Hy-17634

37. J3.646.120i

38. D10814

39. 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide

40. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-((1r,2r)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide

41. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-[(1r,2r)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop

42. (3ar,7s,10s,12r,21e,24ar)-7-tert-butyl-n-{(1r,2r)-2- (difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro- 5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12- Methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10- Carboxamide Hydrate

43. Cyclopropanecarboxamide, N-((((1r,2r)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-l-valyl-(4r)-4-hydroxy-l-prolyl-1-amino-2-(difluoromethyl)-n-((1-methylcyclopropyl)sulfonyl)-, Cyclic (1->2)-ether, (1r,2r)-

44. Ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1h,10h-9,12-methanocyclopenta[18,19][1,10,17,

2.4 Create Date

2012-11-30

3 Chemical and Physical Properties

Molecular Formula	C₃₈H₄₆F₄N₆O₉S
Molecular Weight	838.9 g/mol
XLogP3	4.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	15
Rotatable Bond Count	7
Exact Mass	838.29831089 g/mol
Monoisotopic Mass	838.29831089 g/mol
Topological Polar Surface Area	204 Å²
Heavy Atom Count	58
Formal Charge	0
Complexity	1760
Isotope Atom Count	0
Defined Atom Stereocenter Count	7
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.

FDA Label

Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.

Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.

5 Pharmacology and Biochemistry

5.1 Pharmacology

In a biochemical assay studying clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a, glecaprevir displayed IC50 values ranging from 3.5 to 11.3 nM that resulted in inhibition of the proteolytic activity of recombinant NS3/4A enzymes. In HCV replicon assays, glecaprevir had median EC50 values of 0.08-4.6 nM against laboratory and clinical isolates from subtypes 1a, 1b, 2a, 2b, 3a, 4a, 4d, 5a, and 6a. In a QT study, glecaprevir is not shown to prolong the QTc interval.

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

GLECAPREVIR

5.2.2 FDA UNII

K6BUU8J72P

5.2.3 Pharmacological Classes

Mechanisms of Action [MoA] - UGT1A1 Inhibitors

5.3 ATC Code

J05AP57

5.4 Absorption, Distribution and Excretion

Absorption

In healthy subjects, the time it takes to reach the peak plasma concentration (Tmax) is approximately 5 hours. The mean peak plasma concentration (Cmax) is 597ng/mL in non-cirrhotic HCV-infected subjects. Relative to fasting conditions, the consumption of meals increases the absorption of glecaprevir by 83-163%.

Route of Elimination

The predominant route of elimination of the drug is biliary-fecal, where 92.1% of administered drug is excreted in feces and 0.7% of the drug is excreted in the urine.

5.5 Metabolism/Metabolites

Glecaprevir undergoes limited secondary metabolism in vitro, predominantly by CYP3A.

5.6 Biological Half-Life

The elimination half life (t1/2) is approximately 6 hours.

5.7 Mechanism of Action

Glecaprevir is an inhibitor of the HCV NS3/4A protease, which is a viral enzyme necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins. These multifunctional proteins, including NS3, are essential for viral replication. The N-terminal of NS3 protein confers serine protease activity, whileThe C-terminus of NS3 encodes a DExH/D-box RNA helicase which hydyolyzes NTP as an energy source to unwind double-stranded RNA in a 3 to 5 direction during replication of viral genomic RNA. NS4A is a cofactor for NS3 that directs the localization of NS3 and modulates its enzymatic activities. Glecaprevir disrupts the intracellular processes of the viral life cycle through inhibiting the NS3/4A protease activity of cleaving downstream junctions of HCV polypeptide and proteolytic processing of mature structural proteins.

API SUPPLIERS